Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles Alimentary Pharmacology & Therapeutics (Suppl) Year : 2023

Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply

Abstract

No abstract available
Fichier principal
Vignette du fichier
2023_Buisson_Aliment-Pharmacol_Therapeutics.pdf (176.19 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-04056456 , version 1 (03-04-2023)

Licence

Identifiers

Cite

Anthony Buisson. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply. Alimentary Pharmacology & Therapeutics (Suppl), 2023, 57 (6), pp.735-736. ⟨10.1111/apt.17405⟩. ⟨hal-04056456⟩
32 View
24 Download

Altmetric

Share

More